Insulin resistance is one of the major factors contributing to metabolic diseases, but the underlying mechanisms are still poorly understood. As an important cofactor, B-cell translocation gene 1 (BTG1) is involved in many physiologic processes; however, the direct effect of BTG1 on insulin sensitivity has not been described. In our study, BTG1 overexpression or knockdown improved or impaired insulin signaling in vitro, respectively. In addition, adenovirus-mediated BTG1 overexpression improved insulin sensitivity in wild-type (WT) and insulin-resistant leptin-receptor mutated (db/db) mice. In addition, transgenic BTG1-overexpressing mice were resistant to high-carbohydrate diet-induced insulin resistance. Adenovirus-mediated BTG1 knockdown consistently impaired insulin sensitivity in WT and insulinsensitive leucine-deprived mice. Moreover, hepatic BTG1 expression was increased by leucine deprivation via the mammalian target of rapamycin/ribosomal protein S6 ki-
development of novel therapeutic approaches to treatment of T2D and other related metabolic diseases.
The proteins of B-cell translocation gene (BTG)/ transducer of the ErbB2 (Tob) family are characterized by similarities in their amino terminal region: the BTG1 homology domain (2) . The mammalian BTG/Tob family comprises 6 proteins (BTG1, BTG2/PC3/Tis21, BTG3/ ANA, BTG4/PC3B, Tob1/Tob, and Tob2) (3) . A biologically common feature of proteins in this family is their inhibition of cell proliferation (2, 3) . Recent work has implied that these family members have a role in the maintenance of blood glucose homeostasis (4, 5) . For example, it has been shown that the tolerance to glucose or insulin administration is not much different between TOB2 2/2 and control mice (5) . In contrast, overexpression of BTG2 increases hepatic gluconeogenic gene expression and blood glucose output and subsequently impairs glucose and insulin tolerance in mice (4) .
BTG1 was first identified as a translocation gene in a case of B-cell chronic lymphocytic leukemia (6) and is highly conserved among various species (2) . As a cofactor, BTG1 interacts with other transcription factors to exert its effect (2, 3) . Recent studies have implicated BTG1 as having a role in the pathogenesis of several diseases, including multiple sclerosis (7) and cancer (8, 9) . However, the physiologic function of BTG1 in the regulation of insulin sensitivity remains completely unknown. Based on previous studies on BTG2 (4) , we speculated that BTG1 is also essential in the regulation of insulin sensitivity and glucose metabolism. The purpose of the current study was to investigate this possibility and elucidate underlying mechanisms.
In this work, BTG1 strongly influenced insulin signaling and insulin sensitivity in vitro and in vivo, in normal and insulin-resistant or -sensitive conditions. Furthermore, the effect of BTG1 on insulin sensitivity was mediated by regulating c-Jun expression, which is controlled by it effects on the actions of c-Jun and retinoic acid receptor (RAR). Taken together, these results identify a novel function for hepatic BTG1 in Abbreviations: AP, activator protein; AKT, protein kinase B; BTG, B-cell translocation gene; db/db mice, leptin receptor-mutated mice; GFP, green fluorescent protein; GSK, glycogen synthase kinase; GTT, glucose tolerance test; HCD, high-carbohydrate diet; HOMA, homeostasis model assessment; ITT, insulin tolerance test; IR, insulin receptor;
(continued on next page) the regulation of insulin sensitivity and provide important insights into the nutritional regulation of BTG1 expression.
MATERIALS AND METHODS

Chemicals and plasmids
Insulin and glucagon was from Sigma-Aldrich (St. Louis, MO, USA). The cDNA of mouse BTG1 was amplified from mouse liver genomic DNA and inserted into the expressing vector pcDNA 3.1/myc-His (Invitrogen, Carlsbad, CA, USA). The hemagglutinin-tagged, constitutively active S6K1 expression plasmid was the Addgene plasmid 8991, originally from John Blenis' laboratory (Weill Cornell Medical College, New York, NY, USA). The human RARa plasmid was kindly provided by Dr. Guang Ning (Rui-Jin Hospital, Shanghai, China) (10). Doublestranded small interfering (si)RNA targeting mouse/human BTG1 or c-Jun was from GenePharma (Shanghai, China).
Generation of recombinant adenoviruses
Recombinant adenovirus-expressing MYC-tagged mice BTG1 (Ad-BTG1) were generated with the AdMax Adenoviral Vector Creation System (Microbix Biosystems, Inc., Mississauga, ON, Canada) according to the manufacturer's instructions. Adenoviruses expressing scrambled sequence (Ad-scramble), short hairpin (sh)RNA against the coding region of BTG1 (Ad-shBTG1) or c-Jun (Ad-sh-cJun) were generated with the BOLCK-iT adenoviral RNA interference (RNAi) expression system (Invitrogen), according to the manufacturer's instructions. The scrambled sequence is 59-TTCTCCGAACG TGTCACGT-39. The sequence for BTG1 knockdown is 59-GGATCAGGTTAC CGTTGTATT-39 and for c-Jun is 59-GCAAAGATGGAAACGACCTTC-39. Viruses were purified by ultracentrifugation in cesium chloride gradient and then quantified (11) . , and BTG1 protein (top, Western blot; bottom, quantitative measurements of p-IR, p-AKT, p-GSK3b, and BTG1, relative to their total protein or actin). Data (means 6 SEM) are representative of results in at least 3 independent in vitro experiments. Statistical significance was calculated with the 2-tailed Student's t test for the effects of Ad-BTG1 or Ad-shBTG1 vs. the control group. *P , 0.05.
(continued from previous page) mTOR, mammalian target of rapamycin; RAR, retinoic acid receptor; RNAi, RNA interference; shRNA, short-hairpin RNA; SNK, Student-Newman-Keuls (test); T2D, type 2 diabetes; Tob, transducer of ErbB; WT, wild type
Animals and treatment
Male C57BL/6J wild-type (WT) mice were from Shanghai Laboratory Animal Co., Ltd. (Shanghai Laboratory Animal Center, Shanghai, China). Leptin receptor-mutated (db/db) mice were from the Model Animal Research Center of Nanjing University (Nanjing, China). In the current study, we used BTG1 transgenic (BTG1 Tg) mice on a C57BL/6J background, produced by crossing our originally generated FVB/ N background BTG1 Tg mice (Cyagen Biosciences, Inc., Guangzhou, China) with C57BL/6J WT mice for at least 4 generations. Tail biopsies were analyzed by genomic PCR (forward primer, 59-TGGCTAACTAGAGAACCCACT-39; reverse primer, 59-CTGTCTACCATTTGCACGTT-39). Six-weekold male C57BL/6J WT and BTG1 Tg mice were fed ad libitum for 4 wk continuously, on either a high-carbohydrate diet (HCD) or a control diet (Research Diets, Inc., New Brunswick, NJ, USA). The compositions of the HCD and control diet have been published (12) . Eight-to 10-wk-old mice were maintained on a 12 h light-dark cycle at 25°C with free access to water. Control diet (a nutritionally complete amino acid) and (2) Leu (leucine-deficient) diet (Research Diets, Inc.) feeding experiments were performed as has been described previously (11) . Viruses were diluted in PBS and administered at a dose of 10 9 plaque-forming units per mouse via intravenous injection of the tail vein. Animal experiments were conducted in accordance with the guidelines of the Institute for Nutritional Science (Shanghai Institutes for Biologic Sciences, Chinese Academy of Sciences). Animals were killed by CO 2 inhalation.
Isolation of primary hepatocytes, cell culture, and treatment Primary hepatocytes were prepared by collagenase perfusion (13) . Cells were transfected with plasmids by using Effectene transfection reagent (Qiagen, Hilden, Germany) or were infected with viruses at a dose of 10 7 plaque-forming units per well in 12-well plates. Control and (2) Leu medium were prepared as described elsewhere (11) .
Detection of mRNAs and proteins mRNA and protein levels were examined by RT-PCR and Western blot (11) . Primer sequences used for RT-PCR were as follows: Mmu-GAPDH, 59-TGTGTCCGTCGTGGA 
Insulin and glucose test
Blood glucose levels were measured with a Glucometer Elite monitor (Bayer, Pittsburgh, PA, USA). Serum insulin levels were measured with the Mercodia Ultrasensitive Rat Insulin ELISA kit (Alpco Diagnostics, Salem, NH, USA). Glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) were performed by injection of 2 g/kg i.p. glucose in mice unfed overnight and 0.75 U/kg i.p. insulin in those remaining unfed for 4 h, respectively. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated according to the formula: [unfed glucose levels (millimoles per liter)] 3 [unfed serum insulin (microunits per milliliter)]/22.5 (14) . The in vivo insulin signaling assay was performed as described elsewhere (13) .
Statistics
All data are expressed as means 6 SEM. Significance was assessed by a 2-tailed Student's t test or 1-way ANOVA, followed by the Student-Newman-Keuls (SNK) test. P , 0.05 denoted statistical significance.
RESULTS
BTG1 regulates insulin signaling in vitro
To determine whether BTG1 has a direct effect on insulin signaling in liver, we infected HepG2 cells and primary Figure 3 . Ad-BTG1 improves insulin sensitivity in db/db mice. A) Hepatic BTG1 was analyzed in male C57BL/6J WT and db/db mice. B-E ) Male C57BL/6J db/db mice were injected with Ad-BTG1 (+Ad-BTG1) or Ad-GFP (2Ad-BTG1) via the tail vein, followed by measurement of fed or unfed blood glucose and serum insulin levels at d 11 and 5, respectively (C, D), and performance of GTT and ITT tolerance tests at d 5 and 7, respectively (E ). Data (means 6 SEM) are representative of results in at least 2 independent in vivo experiments (n = 5-7). Statistical significance was calculated by using the 2-tailed Student's t test for the effects of db/db vs. WT mice (A), or Ad-BTG1 vs. Ad-GFP injection in db/db mice (B-E ): *P , 0.05. A, B) Btg1 mRNA and BTG1 protein (top, Western blot; bottom, quantitative measurement of BTG1 proteins relative to actin); blood glucose levels (C ); serum insulin levels (D); and GTT and ITT (E ). cultured murine hepatocytes with adenoviruses expressing MYC-BTG1 (Ad-BTG1) or control green fluorescent protein (Ad-GFP). Insulin-stimulated phosphorylation of IR (Tyr 1150/1151 ), protein kinase B (AKT; Ser 473 ), and GSK3b (Ser 9 ), the 3 major components of insulin signaling (15) , was increased in cells overexpressing BTG1 compared with control cells (Fig. 1A) . The opposite effect was observed when endogenous BTG1 protein was reduced by adenoviruses expressing smallhairpin (sh)RNA for BTG1 (Ad-shBTG1) compared with those infected with scrambled adenovirus (Adscrambled) (Fig. 1B) .
Ad-BTG1 improves insulin sensitivity in normal conditions in vivo
To investigate the effect of BTG1 in vivo, we infected male C57BL/6J WT mice with Ad-BTG1 or Ad-GFP via tail vein injection. We observed increased hepatic BTG1 expression in the Ad-BTG1 mice ( Fig. 2A) . Levels of blood glucose and serum insulin decreased in the Ad-BTG1 mice in both fed and unfed conditions (Fig. 2B, C) . Ad-BTG1 also decreased the HOMA-IR index consistently (Fig. 2D) . Glucose tolerance and clearance were improved in Ad-BTG1 mice, as demonstrated by GTTs and ITTs, respectively (Fig. 2E) . In addition, insulin-stimulated phosphorylation of IR, AKT, and GSK3b was increased in the livers of the Ad-BTG1 mice (Fig. 2F ).
Ad-BTG1 improves insulin sensitivity in insulinresistant conditions in vivo
After considering the above results, we speculated that hepatic BTG1 expression is decreased in insulin-resistant mice. To test this possibility, we examined hepatic BTG1 expression in 2 animal models of insulin resistance: one caused by a genetic defect in leptin-receptor (db/db) (16) and the other by an HCD (17) . We found that hepatic BTG1 expression was decreased in db/db mice compared with that in WT mice (Fig. 3A) . The reduction of BTG1 in insulin-resistant conditions led to the postulation that increased expression of BTG1 relieves insulin resistance. We then injected male C57BL/6J db/db mice with Ad-BTG1 or Ad-GFP and found that overexpression of hepatic BTG1 in db/db mice significantly decreased blood glucose levels in both the fed and unfed state, but had no effect on serum insulin levels ( Fig. 3B-D) . Ad-BTG1 db/db mice also exhibited improved glucose tolerance and clearance (Fig. 3E) .
As observed in db/db mice (Fig. 3A) , we found that hepatic BTG1 expression decreased in HCD-fed mice compared with control mice (Fig. 4A) . To explore the possible involvement of BTG1 on HCD-induced insulin resistance, we generated BTG1 Tg mice, which exhibited significantly increased hepatic BTG1 expression vs. that in control mice (Fig. 4B ). Then these mice and WT mice were fed with a control diet or an HFD for 4 wk. The HCD had no effect on fed blood glucose but increased unfed blood glucose in WT mice, whereas both fed and unfed blood glucose were much lower in BTG1 Tg mice than in WT mice on an HCD (Fig. 4C) . However, serum insulin levels were increased by the HCD in WT and BTG1 Tg mice (Fig. 4D) . The HOMA-IR index was lower in BTG1 Tg mice than in WT mice on a control diet or an HCD (Fig. 4E) . BTG1 Tg mice consistently exhibited improved glucose tolerance and clearance (Fig. 4F) . Furthermore, insulin-stimulated phosphorylation of IR, AKT, and GSK3b, was increased in primary hepatocytes isolated from BTG1 Tg mice compared with those from WT mice (Supplemental Fig. 1A) . In addition to HCD, we found that BTG1 expression increased in the unfed state and decreased with the addition of glucagon and insulin (Supplemental Fig. 2) Ad-shBTG1 attenuates insulin sensitivity in vivo
We further explored whether hepatic BTG1 knockdown would have the opposite effect in male C57BL/6J WT mice injected with Ad-shBTG1 or Ad-scrambled. Inhibition of hepatic BTG1 significantly increased unfed blood glucose . Ad-shBTG1 decreases leucine deprivation-enhanced insulin sensitivity in vitro and in vivo. A, B) Male C57BL/6J WT mice were fed a control (+Leu) or leucine-deficient (2Leu) diet for 7 d. HepG2 cells were incubated in control (+Leu) or leucine-deficient (2Leu) medium for 24 h. C ) HepG2 cells were infected with Ad-shBTG1 (+Ad-shBTG1) or Ad-scrambled (2Ad-shBTG1) for 48 h before being incubated in (2) Leu or (+) Leu medium for 24 h, followed by stimulation with 100 nM insulin for 20 min. D-I ) Male C57BL/6J WT mice were injected with Ad-shBTG1 (+Ad-shBTG1) or Ad-scrambled (2Ad-shBTG1) for 2 d, followed by the (+) Leu or (2) Leu) diet. Hepatic BTG1 expression was examined at d 9 (D); fed or unfed blood glucose (E ) and serum insulin (F ) levels were measured at d 5 and 6, respectively; GTTs and ITTs were performed at d 6 and 8, respectively (H ); and insulin signaling in liver was examined before (2Ins) and after (+Ins) 2 U/kg insulin stimulation for 3 min (continued on next page) levels and HOMA-IR index, although it had no effect on fed blood glucose and serum insulin levels (Fig. 5A-D) . As predicted, Ad-shBTG1 injection also impaired glucose tolerance, insulin sensitivity, and insulin signaling in liver (Fig. 5E, F) .
Ad-shBTG1 decreases leucine deprivation-improved insulin sensitivity in vitro and in vivo
We have shown that leucine deprivation increases insulin sensitivity (11) . In the current study, BTG1 expression increased significantly in HepG2 cells incubated with (2) Leu medium and livers of mice fed with (2) Leu diet (Fig. 6A,  B) , suggesting that BTG1 is involved in the regulation of leucine deprivation-improved insulin sensitivity.
To test this possibility, we infected HepG2 cells with AdshBTG1 or Ad-scrambled and found that BTG1 knockdown attenuated leucine deprivation-stimulated insulin signaling (Fig. 6C) . As observed in vitro, inhibition of BTG1 blocked the effects of leucine deprivation on decreasing unfed blood glucose and HOMA-IR index and increasing glucose tolerance and clearance ( Fig. 6D-H) . Leucine deprivation-stimulated phosphorylation of IR, AKT, and GSK3b after insulin stimulation was decreased in the livers of Ad-shBTG1 mice (Fig. 6I) .
The mammalian target of rapamycin (mTOR)/S6 kinase (K)1 signaling pathway couples leucine deprivation to improved insulin sensitivity (11) , suggesting that the mTOR/S6K1 pathway regulates BTG1 expression during leucine deprivation. Consistent with this possibility, activation of S6K1 blocked leucine deprivation-induced BTG1 expression in vitro and in vivo (Fig. 6J) .
Ad-BTG1 improves insulin sensitivity by increasing cJun expression in hepatocytes in vitro and in vivo c-Jun regulates insulin signaling (18) , and its activity is controlled by BTG1 (19) , suggesting that c-Jun mediates the effects of BTG1 on insulin sensitivity. As predicted, c-Jun expression was increased by Ad-BTG1 or decreased by AdshBTG1 in HepG2 cells and mouse liver (Fig. 7A-D) . c-Jun expression also increased in primary hepatocytes isolated from BTG1 Tg mice compared with those from WT mice (Supplemental Fig.1B, C) . The possible involvement of c-Jun in BTG1-stimulated insulin signaling was then investigated in primary hepatocytes when endogenous c-Jun protein was reduced via RNAi. c-Jun knockdown alone decreased insulin signaling and significantly blocked BTG1-enhanced insulin signaling in these cells (Fig. 7E) .
To gain further insight into the importance of c-Jun in regulating insulin sensitivity by BTG1 in vivo, we injected male C57BL/6J WT mice with adenovirus expressing Adsh-cJun or Ad-scrambled and found that insulin sensitivity and hepatic insulin signaling were attenuated in Adsh-cJun mice (Supplemental Fig. 3) . Although Ad-shc-Jun had no effects on unfed blood glucose and fed serum insulin, it increased fed blood glucose levels and the HOMA-IR index in Ad-BTG1 mice (Fig. 7F-I ). In addition, in Ad-sh-cJun mice, Ad-BTG1-improved glucose and insulin tolerance were attenuated (Fig. 7J) .
BTG1 regulates c-Jun expression by affecting the transcriptional activity of c-Jun and RARa
Activated protein (AP)-1 is a hetero-or homodimeric complex that comprises members of the Jun and FOS protein families, and the c-Jun promoter contains a highaffinity binding site for the AP-1 complex (20) . There is a regulatory circuit in which AP-1 activates the c-Jun promoter and gene expression, and expression of c-Jun in turn enhances AP-1 activity, thereby potentiating c-Jun expression (20) . As BTG1 is a cofactor of c-Jun (19) , it may regulate c-Jun expression via this regulatory circuit. Consistent with this possibility, c-Jun silencing suppressed c-Jun promoter activity, and this effect was prevented by coexpression of BTG1 in HEK293T cells (Fig. 8A) .
In addition, BTG1 stimulates the transcriptional activity of RAR (19) , and RAR stimulates the c-Jun promoter (21) , suggesting the involvement of RAR in BTG1-mediated c-Jun expression. Indeed, although RARa expression was not altered, the expression of RARa well-known downstream target CD38 (22) was increased by Ad-BTG1 or decreased by Ad-shBTG1 in liver (Fig. 8B, C) . Consistent with this hypothesis, Ad-shBTG1 attenuated RARa stimulation of c-Jun expression in HepG2 cells (Fig. 8D) . Furthermore, RARa-stimulated c-Jun promoter activity was prevented by BTG1 knockdown in HepG2 cells (Fig. 8E) . Finally, overexpression of RARa blocked Ad-shBTG1's effects on decreasing insulin signaling (Fig. 8F) .
DISCUSSION
BTG1 is present in many tissues, including liver, brain, and lung (23) . However, most biologic functions of BTG1 are identified in a variety of cells (2), and the function of BTG1 in vivo is poorly understood. In BTG1-null mice, one study showed that BTG1 is necessary for generating new adult neurons (24). In the current study, we showed a novel on d 9 (I ). J ) HepG2 cells were transfected with plasmid expressing CA-S6K1 (+CA-S6K1) or control vector (2CA-S6K1) for 24 h before being incubated with (2) Leu medium for 24 h. Mice were injected with Ad-CAS6K1 (+Ad-CA-S6K1) or Ad-GFP (2Ad-CA-S6K1) via the tail vein, followed by a (2) Leu diet for 7 d. Data (means 6 SEM) are representative of results in at least 3 independent in vitro experiments or at least 2 independent in vivo experiments (n = 5-7). Statistical significance was calculated with the 2-tailed Student's t test or 1-way ANOVA, followed by the SNK test for the effects of (2) function of hepatic BTG1 in regulating insulin sensitivity in mice, as demonstrated by the fact that whole-body and hepatic insulin sensitivities were improved or impaired in mice with BTG1 overexpression and knockdown, respectively. We speculate that BTG1 has a direct effect on insulin signaling, on the basis of results obtained from our in vitro study showing that insulin signaling was increased or decreased by overexpression and knockdown of BTG1, respectively, in HepG2 cells and primary hepatocytes. Furthermore, in contrast to what we observed for BTG1, BTG2, (the closest homolog of BTG1), which shares 66% homology, impairs insulin sensitivity in mice (4), and another member, TOB2, has no effect (5). The difference in the regulation of insulin sensitivity among different BTG family members could be the dissimilarity in their primary structure. These results also suggest that each protein in the BTG/TOB family has its unique impact on insulin sensitivity, and the metabolic function of members in this family varies-a possibility that warrants additional study. In addition to testing the effect of BTG1 on insulin sensitivity in normal conditions, we explored the possible involvement of BTG1 in insulin-resistant and -sensitive conditions. We found unexpectedly that hepatic BTG1 expression was decreased in genetic and dietary-induced insulin-resistant mice and increased in insulin-sensitive mice. Manipulation of BTG1 expression reversed the insulin-resistant or -sensitive phenotype in these models. These results suggest that BTG1 plays a broad role in different metabolic conditions. Until now, nutritional regulation of BTG1 expression has been poorly understood. A study showed that BTG1 expression is increased in rat liver during proteincalorie malnutrition (25) . In the current study, BTG1 expression was up-regulated by leucine deprivation. S6K1 is a downstream target of mTOR, both of which are serine/threonine protein kinases that regulate cell growth, cell proliferation, cell survival, protein synthesis, and transcription (26) . Leucine deprivation downregulated mTOR/S6K1 activity (11) , suggesting that the mTOR/S6K1 signaling pathway is necessary for the increase in BTG1 during leucine deprivation. This possibility was confirmed by the inhibitory effect of CA-S6K1 on leucine deprivation-induced BTG1 expression. Furthermore, we found that BTG1 expression was decreased by an HCD, glucagon, and insulin and was increased in the unfed state through underlying molecular mechanisms that remain to be studied. These results greatly extend the knowledge of nutritional control of BTG1 expression and also increase understanding of the role of BTG1 in different nutritional conditions. BTG1 regulates genes expression via interacting with other transcription factors as a cofactor (19, (27) (28) (29) . One of these transcription factors is c-Jun (19), a primary component of the AP-1 transcription complex that is involved in diverse biologic processes (30) . c-Jun regulates transcription of phosphoinositide-dependent kinase (PDK)-1, with a concomitant impact on AKT activity (18) , suggesting the involvement of c-Jun in regulating insulin sensitivity. Indeed, we observed that c-Jun expression was upregulated by BTG1. Adenovirus-mediated knockdown of c-Jun significantly decreased insulin sensitivity in vivo and in vitro. It also blocked BTG1-enhanced insulin sensitivity. These results not only demonstrate an important role of cJun in mediating BTG's effect, but also provide direct evidence of an in vivo effect of c-Jun in the regulation of insulin sensitivity.
Furthermore, we found that BTG1 regulates c-Jun expression by stimulating c-Jun and RAR, given that AP-1 can activate the c-Jun promoter and expression because the cJun promoter contains an AP-1 binding site. Expression of c-Jun in turn further enhances AP-1, thereby potentiating its own gene promoter activation in a self-regulatory circuit (20) . The reasons for the latter possibility are based on a study that showed that BTG1 can interact with RAR (19) . In the current study, BTG1 did not affect RAR expression, but attenuated RAR's activation of c-Jun expression and its promoter activity in vitro. The involvement of other transcription factors in BTG1-regulated insulin sensitivity should be studied further. In summary, as described in our working model (Fig. 8G) , we identified a novel function of BTG1 in the regulation of insulin sensitivity in conditions of normal and altered insulin sensitivity. Furthermore, the effect of BTG1 was mediated via up-regulation of c-Jun expression, by stimulating c-Jun and RAR activation. These results provide important insights into the molecular mechanisms underlying insulin resistance and suggest a strategy for treating metabolic disorders.
